Glycine

證據等級: L5

預測適應症: 10 個

Glycine: From No Registered SAHPRA Indication to Predicted Nasal Cavity Disease Treatment

One-Sentence Summary

Glycine currently has no SAHPRA-registered product and no documented original indication or mechanism of action in this evidence pack. The TxGNN model predicts a possible role in Nasal Cavity Disease (score 99.85%), but the only supporting clinical trial and literature identified are unrelated to glycine’s pharmacology — this is a low-confidence, model-only signal, not a clinically supported repurposing candidate.

Quick Overview

Item	Content
Original Indication	Not available — no SAHPRA licence and no original indication data on file
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.85%
Evidence Level	L5 (model prediction only, no supporting studies)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for glycine is not available in this evidence pack, and no original indication is on record — so the usual “original MOA → new indication” reasoning chain cannot be built here.

Reviewing the actual evidence retrieved for this prediction, the link appears weak. The one associated clinical trial (NCT01806675) studies a PET imaging tracer (¹⁸F‑FPPRGD2) for integrin expression in cancer patients and does not involve glycine as a therapeutic agent — it only shares an anatomical search term with “nasal cavity.” The two literature hits are similarly tangential: a 1995 veterinary histochemistry study of bovine nasal mucosa, and a 2018 study of oligoarginine-polymer mucosal adjuvants — neither investigates glycine’s pharmacological effect on nasal disease.

The evidence pack’s own analysis concludes there is no clear mechanistic rationale connecting glycine (an inhibitory neurotransmitter / NMDA receptor co-agonist) to nasal cavity disease. This pattern is consistent with a TxGNN embedding-space artefact rather than a genuine pharmacological signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01806675	Phase 1/2	Completed	25	Evaluated ¹⁸F-FPPRGD2 PET/CT/MRI imaging of αvβ3 integrin expression in glioblastoma, gynaecological cancer, and renal cell carcinoma patients on antiangiogenic therapy. Does not involve glycine as a treatment; trial relevance to nasal cavity disease is coincidental (imaging biomarker study only).

No SANCTR or PACTR-registered trials were identified for this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
7771054	1995	Veterinary histochemistry	Veterinary Pathology	Lectin histochemistry of bovine nasal mucosa in herpesvirus infection and Pasteurella haemolytica adhesion; no glycine intervention studied.
29607903	2018	Preclinical (polymer adjuvant)	Chemical & Pharmaceutical Bulletin	Oligoarginine-conjugated polymer as a nasal mucosal vaccine adjuvant; glycine not the study agent.

Neither publication provides direct pharmacological evidence for glycine in nasal cavity disease.

South Africa Market Information

Currently no SAHPRA registrations are on file for glycine as a marketed pharmaceutical product (market status: Not marketed, 0 licences recorded in this evidence pack).

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Note: key warnings, contraindications, and drug interaction data are currently unavailable for glycine in this evidence pack — this is flagged as a blocking data gap for any safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: The only clinical trial and literature identified for the Nasal Cavity Disease prediction are pharmacologically unrelated to glycine, and the model itself provides no plausible mechanistic link. Combined with L5 evidence (prediction-only) and the absence of any SAHPRA registration or PI safety data, this candidate does not currently support further evaluation.

To proceed, the following is needed:

SAHPRA/TFDA Professional Information (warnings, contraindications) — currently a blocking data gap
Confirmed mechanism of action (MOA) data from DrugBank or equivalent source
A clinical trial or literature search specifically targeting glycine (not tracer/adjuvant studies that merely share search terms) before this indication is reconsidered
If further evaluation is desired, the evidence pack’s rank-5 candidate (dyspepsia, L4 evidence, “Research Question” stage) has a more coherent mechanistic rationale (glycine as NMDA receptor co-agonist affecting gastric accommodation) and may be a more productive direction than nasal cavity disease
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.